Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769441 | 0.79 | TSHR (0.33) | TSHRNLRP3 | |
| SCHEMBL29809963 | 0.76 | — | — | |
| SCHEMBL1472140 | 0.72 | — | — | |
| SCHEMBL1976528 | 0.72 | — | — | |
| SCHEMBL8719762 | 0.69 | TP53 (0.31) | — | |
| SCHEMBL20581719 | 0.68 | — | — | |
| SCHEMBL1415573 | 0.67 | — | — | |
| SCHEMBL31402658 | 0.67 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL18048378 | 0.67 | TSHR (0.30) | TSHRNLRP3 | |
| SCHEMBL3501857 | 0.67 | TSHR (0.30) | TSHRNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORP (US) | 2018-03-08 | — | — | US | disclosed |
| US-9718855-B2 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA and as diagnostics tools | CHEMGENES CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORPORATION (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785619-B1 | Nucleosides and oligonucleotides for studies on reversal of cytotoxic and mutagenic damage of DNA potential diagnostics tools | CHEMGENES CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2012075005-A1 | COMPOUNDS FOR THE SYNTHETIC INTRODUCTION OF N-ALKYL NUCLEOSIDES INTO DNA OLIGONUCLEOTIDES | BERRY & ASSOCIATES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142908-A1 | COMPOUNDS FOR THE SYNTHETIC INTRODUCTION OF N-ALKYL NUCLEOSIDES INTO DNA OLIGONUCLEOTIDES | BERRY AND ASSOCIATES, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110009607-A1 | METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END | THE UNIVERSITY OF TOKYO (JP) | 2011-01-13 | — | — | US | disclosed |
| US-5614617-A | ENZYME RESISTANCE FOR GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142908-A1 | COMPOUNDS FOR THE SYNTHETIC INTRODUCTION OF N-ALKYL NUCLEOSIDES INTO DNA OLIGONUCLEOTIDES | NSUN2, POLN, NT5C3B | TSHR 1190/4885NLRP3 4372/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | TSHR 510/4885NLRP3 2737/4885 |
| US-20110009607-A1 | METHOD FOR PREPARING DNA FRAGMENT HAVING STICKY END | POLB, POLL, POLN | TSHR 1820/4885NLRP3 4639/4885 |
| US-20140350234-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | TSHR 1132/4885NLRP3 4302/4885 |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | TSHR 1132/4885NLRP3 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.